Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial

Nikkhah, Homayoun; Moez, Reza Niazpour; Entezari, Morteza; Ramezani, Alireza; Hassanpour, Kiana; Karimi, Saeed; Yaseri, Mehdi

doi:10.1007/s00417-021-05169-1

Cited by 6 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain ophthalmic-specific NSAIDs have proven to be effective in mitigating macular edema and enhancing vision. Notable examples include ketorolac, a potent COX-1 inhibitor, and bromfenac, a potent COX-2 inhibitor [149][150][151][152].…”

Section: Anti-inflammatory Drugsmentioning

confidence: 99%

Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune Mechanisms

Tang,

Buonfiglio,

Böhm

et al. 2024

Antioxidants

View full text Add to dashboard Cite

Diabetic retinopathy (DR) represents a severe complication of diabetes mellitus, characterized by irreversible visual impairment resulting from microvascular abnormalities. Since the global prevalence of diabetes continues to escalate, DR has emerged as a prominent area of research interest. The development and progression of DR encompass a complex interplay of pathological and physiological mechanisms, such as high glucose-induced oxidative stress, immune responses, vascular endothelial dysfunction, as well as damage to retinal neurons. Recent years have unveiled the involvement of genomic and epigenetic factors in the formation of DR mechanisms. At present, extensive research explores the potential of biomarkers such as cytokines, molecular and cell therapies, antioxidant interventions, and gene therapy for DR treatment. Notably, certain drugs, such as anti-VEGF agents, antioxidants, inhibitors of inflammatory responses, and protein kinase C (PKC)-β inhibitors, have demonstrated promising outcomes in clinical trials. Within this context, this review article aims to introduce the recent molecular research on DR and highlight the current progress in the field, with a particular focus on the emerging and experimental treatment strategies targeting the immune and redox signaling pathways.

show abstract

Section: Anti-inflammatory Drugsmentioning

confidence: 99%

Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune Mechanisms

Tang,

Buonfiglio,

Böhm

et al. 2024

Antioxidants

View full text Add to dashboard Cite

show abstract

Management of DME: One Minute Preceptor

Mogil

Bakri

2022

Diabetic Macular Edema

View full text Add to dashboard Cite

Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema

2023

View full text Add to dashboard Cite

Purpose To determine the safety and efficacy of adding topical bromfenac 0.09% in the treatment of diabetic macular edema. Methods Seventy patients (70 eyes) with center involved diabetic macular edema with macular thickness (300–500 μm) were included. Patients were divided randomly into two groups: 35 eyes in each group. Both groups were treated with intravitreal ranibizumab monthly for three consecutive months. Bromfenac 0.09% eye drops twice daily was added to the treatment of study group for six months from commencement of treatment. The efficacy of topical bromfenac was evaluated by comparing both groups through follow-up period as regards to visual acuity, central and average thickness and the need for re-injection. Results Patients treated with topical bromfenac in addition to intravitreal ranibizumab revealed significant improvement in visual acuity, more reduction in central and average macular thickness and less tendency to need reinjection compared to those treated with ranibizumab alone (p 0.013, p 0.010 and p 0.022, respectively). No side effects was encountered with the use of topical bromfenac. Conclusion Topical bromfenac 0.09% twice a day could enhance and sustain the efficacy of intravitreal ranibizumab in the treatment of diabetic macular edema without increasing the incidence of corneal side effects.

show abstract

Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial

Cited by 6 publications

References 33 publications

Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune Mechanisms

Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune Mechanisms

Management of DME: One Minute Preceptor

Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema

Contact Info

Product

Resources

About